23.5 C
New York
Saturday, June 13, 2026

Tag: European Union

newssourceFORcompanyinformationcontent1marketreleases

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Action1 Lands at Infosecurity Europe as Autonomous Patching Becomes the New Compliance Standard

America's fastest-growing private software company to demonstrate its autonomous endpoint management platform as Cyber Essentials, NIS2 and DORA redefine compliance expectationsHOUSTON and LONDON, June...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

Transaction in Own Shares

Transaction in Own Shares   

Transaction in Own Shares

Transaction in Own Shares   

Golar LNG Limited Interim results for the period ended June 30, 2025

Highlights and subsequent events

Centrus Announces Pricing of Oversubscribed and Upsized Private Offering of Zero-Coupon Convertible Senior Notes Due 2032

BETHESDA, Md. , Aug. 13, 2025 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) ("Centrus") today announced the pricing of $700 million aggregate principal amount of...

Transaction in Own Shares

Transaction in Own Shares   

Transaction in Own Shares

Transaction in Own Shares   

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options

Progress on share buyback programme

Progress on share buyback programme

Westport Reports Second Quarter 2025 Financial Results

VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. (“Westport") (TSX:WPRT / Nasdaq:WPRT), a supplier of alternative fuel systems and components for the global transportation industry, reported financial results for the second quarter ended June 30, 2025, and provided an update on operations. All figures are in U.S. dollars unless otherwise stated.

Transaction in Own Shares

Transaction in Own Shares   

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEuropean Union

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers